Project 176421
Therapeutic potential of ETA selective antagonist in OA.
Therapeutic potential of ETA selective antagonist in OA.
Project Information
| Study Type: | Unclear |
| Research Theme: | Biomedical |
Institution & Funding
| Principal Investigator(s): | Moldovan, Florina F |
| Institution: | Centre hospitalier universitaire Sainte-Justine (Montréal, Québec) |
| CIHR Institute: | Musculoskeletal Health and Arthritis |
| Program: | |
| Peer Review Committee: | Clinical Investigation - B: Arthritis, Bone, Skin and Cartilage |
| Competition Year: | 2008 |
| Term: | 1 yr 0 mth |
Abstract Summary
Osteoarthritis (OA) is characterised by progressive joint destruction, inflammation and pain. There are no specific ways to stop OA and, because of its nature, only treatments begun during the early stages of the disease can assure those who live with it daily a higher quality of life. The goal of this project is to better understand specific biological factors involved in the evolution of OA. Of these many factors, our laboratory has identified one key potential target for the development of an effective treatments for the painful, degenerating effects of OA by blocking ETA receptor. This project will increase understanding of the processes that take place in early in osteoarthritic joints and how to control those processes. This project could lead to the development of new medications for osteoarthritis.
No special research characteristics identified
This project does not include any of the advanced research characteristics tracked in our database.